financetom
Business
financetom
/
Business
/
Brazil's StoneCo reports 90% profit boost on payment processing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Brazil's StoneCo reports 90% profit boost on payment processing
May 13, 2024 2:03 PM

SAO PAULO, May 13 (Reuters) - Brazilian payment

processor StoneCo ( STNE ) reported on Monday a 90% jump in its

first-quarter adjusted net profit, driven by an increase in its

payments processed.

The company posted an adjusted net profit of 450.4 million

reais ($87.48 million), against an estimate of 462.43 million

reais from analysts polled by LSEG.

Revenue for the quarter grew 13.8% compared to a year

earlier to 3.08 billion reais with the revenues from the firm's

financial services reaching 2.71 billion reais.

StoneCo ( STNE ) said its total payments volume grew 17.9% to

114.3 billion reais, with payments from its micro-, small- and

medium-business (MSMB) segment rising 18.4% year-on-year.

Take rates for the segment, the firm's main business,

grew 0.11 percentage points from the previous quarter to 2.54%,

driven by a "growth in micro and smaller clients, which have

higher take rate," it said.

Its nascent credit portfolio grew 72% from the previous

quarter to 532 million reais. StoneCo's ( STNE ) guidance for this year

is at least 800 million reais.

"The (credit) growth comes in leaps, we had a big jump

in the first quarter, but it won't necessarily continue over the

next three quarters," CEO Pedro Zinner told Reuters in an

interview.

Core earnings, or adjusted earnings before interest,

taxes, depreciation and amortization (EBITDA) came in at 1.51

billion reais, up 20.8% from a year earlier and below analysts'

estimate of 1.61 billion reais.

($1 = 5.1486 reais)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Chemed Reports 'Soft' Q1 as Roto-Rooter Continues to Face Pressure, Oppenheimer Says
Chemed Reports 'Soft' Q1 as Roto-Rooter Continues to Face Pressure, Oppenheimer Says
Apr 26, 2024
12:35 PM EDT, 04/26/2024 (MT Newswires) -- Chemed's ( CHE ) Q1 results were a rare earnings miss as its Roto-Rooter unit continued to face pressure in the quarter coupled with ineffective returns on paid advertising, Oppenheimer said in a note Thursday. Chemed ( CHE ), however, continues to offer an attractive and stable investment opportunity, the research firm said....
Microsoft Delivers Another Strong Quarter with Impressive Results, Wedbush Says
Microsoft Delivers Another Strong Quarter with Impressive Results, Wedbush Says
Apr 26, 2024
12:30 PM EDT, 04/26/2024 (MT Newswires) -- Microsoft ( MSFT ) latest Q3 results showcased yet another strong quarter with impressive outcomes across the board, Wedbush said in a report Friday. Microsoft Azure's growth soared at 31%, surpassing both the Wall Street's estimate of 29% and the company's own guidance of 28%, driven by strong demand for their updated tech...
--Street Color: Amazon's Use of QR Codes Challenged by Union Workers in UK Warehouse
--Street Color: Amazon's Use of QR Codes Challenged by Union Workers in UK Warehouse
Apr 26, 2024
12:41 PM EDT, 04/26/2024 (MT Newswires) -- (Street Color news is derived from real time discussions with market professionals globally subscribed to the Street Color Premium Chat service on Bloomberg IB Chat and the ICE IM. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.) Price: 179.89, Change: +6.22, Percent...
Johnson & Johnson Says Europe's CHMP Recommends Approval of Rybrevant Plus Chemotherapy for Lung Cancer Treatment
Johnson & Johnson Says Europe's CHMP Recommends Approval of Rybrevant Plus Chemotherapy for Lung Cancer Treatment
Apr 26, 2024
12:29 PM EDT, 04/26/2024 (MT Newswires) -- Johnson & Johnson's ( JNJ ) Janssen-Cilag International said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has recommended the approval of Rybrevant (amivantamab), in combination with chemotherapy for the treatment of adult patients with advanced non-small cell lung cancer. The recommendation is supported by the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved